HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (7) Citing Articles via Google Scholar Google Scholar Articles by Puddefoot, J R Articles by Vinson, G P Search for Related Content PubMed PubMed Citation Articles by Puddefoot, J R Articles by Vinson, G P

School of Biological Sciences, Queen Mary, University of London, Mile End Road, London E1 4NS, UK

(Requests for offprints should be addressed to J R Puddefoot; Email: j.r.puddefoot{at}qmul.ac.uk)

As breast cancer remains the most common cause of cancer death in women, there is a continuing need not only to further characterise the processes of cancer progression, but also to improve accuracy of prognostic markers. Breast epithelial cells express components of the renin angiotensin system and studies suggest that these may be altered in disease progression. In addition, altered integrin expression correlates with lymph node metastasis. The aim of this study was to investigate the relationship between angiotensin II (AII) and integrins in breast tissue and, in particular, their role in breast cancer cell metastasis. Using in vitro assays, AII (10^–6 M)-treated MCF-7 and T47D breast cancer cells both show reduced adhesion to extracellular matrix proteins collagen-, fibronectin- and laminin-coated wells (P<0.001) and reduced invasion through collagen-, fibronectin- and laminin-coated membranes (P<0.05). This action was inhibited by co-treatment with the angiotensin type 1 receptor (AT1R) antagonist losartan (10^–5 M). The addition of the AT2R inhibitor PD123319 (10^–5 M) to AII-treated cells had no significant effect. Semi-quantitative reverse transcriptase-PCR and western blotting revealed that cells treated with AII (10^–6 M) expressed lower levels of both integrin 3 and ß1. Using specific inhibitors, this was shown to occur through protein kinase C signalling. These data suggest that AII reduces cell adhesion and invasion through the type 1 receptor and that this effect may be due to reduced expression of integrins, and in particular 3 and ß1.

This article has been cited by other articles:

				D. R. Rhodes, B. Ateeq, Q. Cao, S. A. Tomlins, R. Mehra, B. Laxman, S. Kalyana-Sundaram, R. J. Lonigro, B. E. Helgeson, M. S. Bhojani, et al. AGTR1 overexpression defines a subset of breast cancer and confers sensitivity to losartan, an AGTR1 antagonist PNAS, June 23, 2009; 106(25): 10284 - 10289. [Abstract] [Full Text] [PDF]

				M A Redondo-Muller, M Stevanovic-Walker, S Barker, J R Puddefoot, and G P Vinson Anti-cancer actions of a recombinant antibody (R6313/G2) against the angiotensin II AT1 receptor Endocr. Relat. Cancer, March 1, 2008; 15(1): 277 - 288. [Abstract] [Full Text] [PDF]